Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc (NY: BHC )

24.79 USD -1.66 (-6.28%)
Official Closing Price Updated: 7:26 PM EST, Jan 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Bausch Health Companies Inc

< Previous 1 2 3 4 5 6 7 Next >
Bausch Health To Present At The 37th Annual J.P. Morgan Healthcare Conference
Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in... 
From PR Newswire
Bausch Health To Reduce Debt By Additional $76 Million, Bringing Total Debt Repayment In Quarter To Approximately $400 Million
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it put in notice to pay down an additional $76 million of its senior secured term loans next week, using... 
From PR Newswire
Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has entered into a definitive agreement to acquire certain assets of Synergy Pharmaceuticals Inc.... 
From PR Newswire
Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses
Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that it has received 510(k) clearance from the U.S. Food... 
From PR Newswire
Bausch Health Announces Redemption Of $200 Million Aggregate Principal Amount Of Its Outstanding 5.625% Senior Notes Due 2021
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it will redeem $200 million aggregate principal amount of its outstanding 5.625% Senior Notes due... 
From PR Newswire
Bausch Health Announces Closing Of Incremental Amendment To Its Existing Credit Agreement And Redemption Of Its 7.500% Senior Notes Due 2021
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has entered into an incremental term loan facility amendment (the "Incremental Amendment") to its... 
From PR Newswire
Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today the results to date of its pending cash tender offer (the "Tender Offer"), to purchase any... 
From PR Newswire
Bausch Health Announces Participation In Upcoming Investor Conferences
Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that the company will participate in three upcoming investor conferences. 
From PR Newswire
Bausch + Lomb Reports More Than Five Million Units Of Contact Lens Materials Recycled By Second Anniversary Of ONE By ONE Recycling Program
Bausch + Lomb, a leading global eye health company and a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE:/TSX:BHC), today announced on America Recycles Day that its exclusive ONE by ONE... 
From PR Newswire
Bausch Health Will Expand Contact Lens Manufacturing Facilities In Rochester, NY And Waterford, Ireland
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or "we") today announced it will invest to expand contact lens manufacturing capacity at its Bausch + Lomb sites in... 
From PR Newswire
Bausch Health Commences Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today that it has commenced a cash tender o?er (the "Tender O?er") to purchase any and all of... 
From PR Newswire
Bausch Health To Seek Incremental Amendment To Its Existing Credit Agreement
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that it is seeking to enter into an incremental term loan facility amendment to its existing credit... 
From PR Newswire
Bausch Health To Participate At The Stifel 2018 Healthcare Conference
Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and... 
From PR Newswire
Bausch Health Announces U.S. Launch Of BRYHALI™ (halobetasol propionate) Lotion, 0.01%, For Plaque Psoriasis In Adults
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced it expects to start... 
From PR Newswire
Bausch Health Companies Inc. Announces Third-Quarter 2018 Results
From PR Newswire
Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. launch of... 
From PR Newswire
Dr. Andrew C. Von Eschenbach Joins Bausch Health Board Of Directors
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced its board of directors has elected Dr. Andrew C. von Eschenbach to serve as a director, effective Oct.... 
From PR Newswire
Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease
Salix Pharmaceuticals, Inc. ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned... 
From PR Newswire
Bausch + Lomb To Launch First-In-Class Surgical Support Applications For Stellaris Elite™ Vision Enhancement System On IBM Cloud
Bausch + Lomb, a global eye health company and a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE:/TSX:BHC), and IBM (NYSE: IBM) today announced the new eyeTELLIGENCE™ applications which... 
From PR Newswire
Bausch Health Announces Endowment With The University Of Missouri To Support Student Scholarships
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we") today announced it has established a permanently endowed scholarship fund at the University of Missouri in the... 
From PR Newswire
Bausch Health's Ortho Dermatologics Business To Present New Scientific Data During The Fall Clinical Dermatology Conference
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of... 
From PR Newswire
Bausch Health Companies Inc. Will Release Third-Quarter 2018 Financial Results On November 6
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its third-quarter 2018 financial results on Tuesday, Nov. 6, 2018. Bausch Health will host a conference call and live web... 
From PR Newswire
Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the Journal of... 
From PR Newswire
Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting
Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary... 
From PR Newswire
Bausch Health's BRYHALI™(halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the U.S. Food... 
From PR Newswire
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On Bryhali™* (Halobetasol Propionate) Lotion, 0.01% In The Journal Of Drugs In Dermatology
Ortho Dermatologics, one of the largest prescription dermatology health care businesses, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that the Journal of Drugs... 
From PR Newswire
Salix Resolves Legacy SEC Investigation With No Penalty
Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, and its parent company, Bausch Health... 
From PR Newswire
CORRECTING and REPLACING – Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
Salix Sales Force to Promote First FDA-Approved Drug for Thrombocytopenia in Chronic Liver Disease Patients Scheduled to Undergo a Procedure 
From GlobeNewswire News Releases
Bausch Health Releases First Annual Corporate Social Responsibility Report
Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced the launch of its first annual Corporate Social Responsibility (CSR) Report. The report showcases the Company's responsible, ethical and... 
From PR Newswire
Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
Salix Sales Force to Promote First FDA-Approved Drug for Thrombocytopenia in Chronic Liver Disease Patients Scheduled to Undergo a Procedure 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.